These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 30428932)

  • 1. Herceptin® (trastuzumab) in HER2-positive early breast cancer: a systematic review and cumulative network meta-analysis.
    Wilson FR; Coombes ME; Brezden-Masley C; Yurchenko M; Wylie Q; Douma R; Varu A; Hutton B; Skidmore B; Cameron C
    Syst Rev; 2018 Nov; 7(1):191. PubMed ID: 30428932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Herceptin® (trastuzumab) in HER2-positive early breast cancer: protocol for a systematic review and cumulative network meta-analysis.
    Wilson FR; Coombes ME; Wylie Q; Yurchenko M; Brezden-Masley C; Hutton B; Skidmore B; Cameron C
    Syst Rev; 2017 Oct; 6(1):196. PubMed ID: 29017563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer.
    Miller K; Cortes J; Hurvitz SA; Krop IE; Tripathy D; Verma S; Riahi K; Reynolds JG; Wickham TJ; Molnar I; Yardley DA
    BMC Cancer; 2016 Jun; 16():352. PubMed ID: 27259714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative efficacy of adjuvant trastuzumab-containing chemotherapies for patients with early HER2-positive primary breast cancer: a network meta-analysis.
    Shen Y; Fujii T; Ueno NT; Tripathy D; Fu N; Zhou H; Ning J; Xiao L
    Breast Cancer Res Treat; 2019 Jan; 173(1):1-9. PubMed ID: 30242579
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of Circulating Tumor Cells After Adjuvant Chemotherapy With or Without Anthracyclines in Patients With HER2-negative, Hormone Receptor-positive Early Breast Cancer.
    Schramm A; Schochter F; Friedl TWP; de Gregorio N; Andergassen U; Alunni-Fabbroni M; Trapp E; Jaeger B; Heinrich G; Camara O; Decker T; Ober A; Mahner S; Fehm TN; Pantel K; Fasching PA; Schneeweiss A; Janni W; Rack BK;
    Clin Breast Cancer; 2017 Jul; 17(4):279-285. PubMed ID: 28190761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor-infiltrating lymphocytes in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination: A meta-analysis of randomized controlled trials.
    Solinas C; Ceppi M; Lambertini M; Scartozzi M; Buisseret L; Garaud S; Fumagalli D; de Azambuja E; Salgado R; Sotiriou C; Willard-Gallo K; Ignatiadis M
    Cancer Treat Rev; 2017 Jun; 57():8-15. PubMed ID: 28525810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual Block with Lapatinib and Trastuzumab Versus Single-Agent Trastuzumab Combined with Chemotherapy as Neoadjuvant Treatment of HER2-Positive Breast Cancer: A Meta-analysis of Randomized Trials.
    Clavarezza M; Puntoni M; Gennari A; Paleari L; Provinciali N; D'Amico M; DeCensi A
    Clin Cancer Res; 2016 Sep; 22(18):4594-603. PubMed ID: 27140927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trastuzumab combined with doublet or single-agent chemotherapy as first-line therapy for HER2-positive metastatic breast cancer.
    Yu YF; Wang Y; Fu TP; Chen K; Liu JQ; Yao HR
    Breast Cancer Res Treat; 2018 Apr; 168(2):337-348. PubMed ID: 29188398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concurrent epirubicin and trastuzumab use increases complete pathological response rate without additional cardiotoxicity in patients with human epidermal growth factor receptor 2-positive early breast cancer: A meta-regression analysis.
    Yang MH; Huang CS; Chang DY; Hu FC; Huang SM; Huang PH; Chen IC; Chen TW; Lin CH; Lu YS
    Cancer Med; 2024 Jul; 13(14):e70005. PubMed ID: 39046067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Landscape of neoadjuvant therapy in HER2-positive breast cancer: a systematic review and network meta-analysis.
    Villacampa G; Matikas A; Oliveira M; Prat A; Pascual T; Papakonstantinou A
    Eur J Cancer; 2023 Sep; 190():112885. PubMed ID: 37142539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Feasibility and cardiac safety of trastuzumab emtansine after anthracycline-based chemotherapy as (neo)adjuvant therapy for human epidermal growth factor receptor 2-positive early-stage breast cancer.
    Krop IE; Suter TM; Dang CT; Dirix L; Romieu G; Zamagni C; Citron ML; Campone M; Xu N; Smitt M; Gianni L
    J Clin Oncol; 2015 Apr; 33(10):1136-42. PubMed ID: 25713436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of lapatinib and trastuzumab for HER2-positive breast cancer: a systematic review and meta-analysis of randomised controlled trials.
    Xu ZQ; Zhang Y; Li N; Liu PJ; Gao L; Gao X; Tie XJ
    BMJ Open; 2017 Mar; 7(3):e013053. PubMed ID: 28289045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A systematic review of dual targeting in HER2-positive breast cancer.
    Kümler I; Tuxen MK; Nielsen DL
    Cancer Treat Rev; 2014 Mar; 40(2):259-70. PubMed ID: 24080156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival benefit of anti-HER2 therapy after whole-brain radiotherapy in HER2-positive breast cancer patients with brain metastasis.
    Zhang Q; Chen J; Yu X; Cai G; Yang Z; Cao L; Hu C; Guo X; Sun J; Chen J
    Breast Cancer; 2016 Sep; 23(5):732-9. PubMed ID: 26267412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and cardiac safety of adjuvant trastuzumab-based chemotherapy regimens for HER2-positive early breast cancer.
    Costa RB; Kurra G; Greenberg L; Geyer CE
    Ann Oncol; 2010 Nov; 21(11):2153-2160. PubMed ID: 20351072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis of neoadjuvant pertuzumab and trastuzumab therapy for locally advanced, inflammatory, or early HER2-positive breast cancer in Canada.
    Attard CL; Pepper AN; Brown ST; Thompson MF; Thuresson PO; Yunger S; Dent S; Paterson AH; Wells GA
    J Med Econ; 2015 Mar; 18(3):173-88. PubMed ID: 25347449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant therapy for triple negative and HER2-positive early breast cancer.
    Harbeck N; Gluz O
    Breast; 2017 Aug; 34 Suppl 1():S99-S103. PubMed ID: 28666920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant dual HER2-targeted therapy with lapatinib and trastuzumab improves pathologic complete response in patients with early stage HER2-positive breast cancer: a meta-analysis of randomized prospective clinical trials.
    Hicks M; Macrae ER; Abdel-Rasoul M; Layman R; Friedman S; Querry J; Lustberg M; Ramaswamy B; Mrozek E; Shapiro C; Wesolowski R
    Oncologist; 2015 Apr; 20(4):337-43. PubMed ID: 25732265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of anthracyclines in the treatment of early breast cancer.
    Greene J; Hennessy B
    J Oncol Pharm Pract; 2015 Jun; 21(3):201-12. PubMed ID: 24769570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disease-free survival as a surrogate for overall survival in HR+/HER2- early breast cancer: A correlation analysis.
    Untch M; Pérol D; Mayer EL; Cortes J; Nusch A; Cameron D; Barrios C; Delea T; Danyliv A; Mishra N; Gupta R; Pathak P; Fasching PA
    Eur J Cancer; 2024 May; 202():113977. PubMed ID: 38460476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.